VivoSeq
Oncology

Histiocytosis

37

Pipeline Programs↗

10

Active Trials↗

19

Companies Involved↗

Histiocytosis is a moderately active landscape with 37 programs across 19 companies. The most active players are Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Immunex, Genzyme, a Sanofi Company. 4 therapies are approved with 19 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

6/100

Mech. Concentration

18/100

Completion Rate

80/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

1 program

Phase 1I

Immunex

1 program

Phase 2G

Genzyme, a Sanofi Company

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Pfizer logo

Pfizer

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

34 of 40 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody38%Protein / enzyme25%Cell therapy13%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 100% of 40 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed8 · 31%
Unknown status6 · 23%
Recruiting6 · 23%
Not yet recruiting3 · 12%
Withdrawn1 · 4%
Terminated1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

26 trials

Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
Recruiting·—·Phase 1·NCT06135922·9 enrolled
Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
Recruiting·—·N/A·NCT07488728·80 enrolled
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Recruiting·EElectra Therapeutics Inc.·Phase 2/3·NCT05416307·156 enrolled
Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
Recruiting·—·Phase 2·NCT06160791·36 enrolled
Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study
Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT06614998·80 enrolled
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Recruiting·—·Phase 2·NCT04943198·25 enrolled
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT04551131·10 enrolled
Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT06951971·30 enrolled
Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05762640·20 enrolled
Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 4·NCT06504030·20 enrolled
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
Completed·—·Phase 2·NCT01104025·31 enrolled
Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis
Completed·SSwedish Orphan Biovitrum·Phase 3·NCT03312751·35 enrolled
A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody
Completed·SSwedish Orphan Biovitrum·Phase 2/3·NCT02069899·58 enrolled
Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
Completed·KKarolinska University Hospital·Phase 3·NCT00426101·368 enrolled
Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05063110·35 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)